Opportunities and challenges for the development of dengue vaccine

VernacularTitle:登革热疫苗研发的机遇与挑战
Author: Yinan WANG ; Xin WANG ; Jin SUN ; Min LI ; Ran LIU ; Xia JIN
Publication Type:Journal Article
Keywords: Dengue virus; Immunity; Vaccine; Sanofi Pasteur
From: Chinese Journal of Microbiology and Immunology 2016;36(5):384-389
CountryChina
Language:Chinese
Abstract: Dengue virus(DENV)is an enveloped single positive-stranded RNA virus that belongs to the Flaviviridae family. It is the cause of dengue fever,life-threatening dengue hemorrhagic fever and den-gue shock syndrome. Aedes aegypti and Aedes albopictus are responsible for the wide transmission of DENV in tropical and subtropical regions throughout the world. Currently,there have been several dengue vaccines entering clinical trials,including the Sanofi Pasteur chimeric yellow fever dengue tetravalent vaccine (CYD),which has been licensed for use in some countries. However,CYD does not provide adequate pro-tection against all four serotypes of DENV and induces severe dengue diseases in young and seronegative vac-cine recipients. Therefore,a more efficacious dengue vaccine is still needed. Here,we reviewed the oppor-tunities and challenges for the development of dengue vaccines.